Augmentation therapy with aripiprazole in selective serotonin reuptake inhibitor(SSRI)-refractory obsessive-compulsive disorder(OCD); A randomized double blind placebo controlled trial
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2016
Price : $35 *
At a glance
- Drugs Aripiprazole (Primary) ; Fluvoxamine; Paroxetine
- Indications Obsessive-compulsive disorders
- Focus Therapeutic Use
- Acronyms ROCAAS
- 20 Dec 2016 Status changed from recruiting to discontinued.
- 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 06 Mar 2013 New trial record